Feb 14,2022

ASCENSIA DIABETES CARE PROUDLY SUPPORTS SPARE A ROSE CAMPAIGN FOR FIFTH CONSECUTIVE YEAR

Ascensia Diabetes Care, a global diabetes care company, makers of CONTOUR® blood glucose monitoring (BGM) system portfolio and distributors of the Eversense ® continuous glucose monitoring (CGM) system, announces that it will be supporting the Spare a Rose campaign for the fifth consecutive year.

View Analyst & Ambassador Comments
Go to original news
Feb 14,2022

Nemaura Medical Announces Fiscal Third Quarter 2022 Financial Results and Provides Business Update

Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provides a business update and releases its financial results for the third quarter of fiscal 2022 (for the three months ended December 31, 2021).

View Analyst & Ambassador Comments
Go to original news
Feb 15,2022

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022.

View Analyst & Ambassador Comments
Go to original news
Feb 16,2022

Better Therapeutics Enrolls First Patient in Real World Evidence Study with Colorado Prevention Center Clinical Research

Better Therapeutics, Inc., a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Colorado Prevention Center (CPC) Clinical Research, today announced the first patient has been enrolled in a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001 for the treatment of type 2 diabetes.

COLLABORATION PARTNERSHIP

#r&d

#dtx

View Analyst & Ambassador Comments
Go to original news
Feb 16,2022

Tandem Diabetes Care Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app.

REGULATORY FDA

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 16,2022

Signos Launches a First-of-its-Kind 20,000 Person Study on CGM Use Paired With an AI-Powered Health App to Unlock the Role of Glucose Responses in Health Outcomes for All

Today, Signos announced a first-of-its-kind 20,000 person study on the effects of combining real-time continuous glucose monitor (CGM) use and a mobile health app to improve health outcomes and weight management.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 16,2022

Insulet to Present at Upcoming Investor Conferences

Insulet Corporation announced that management will present at two upcoming investor conferences: The Raymond James & Associates 43rd Annual Institutional Investors Conference on Monday, March 7, 2022, at 1:05 p.m. (Eastern Time), and The Cowen 42nd Annual Health Care Conference (Virtual) on Tuesday, March 8, 2022, at 9:50 a.m. (Eastern Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 17,2022

Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing™: New Horizons

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, is celebrating representation and inclusion for the diabetes community through an activation in the popular Nintendo® video game Animal Crossing™: New Horizons.

View Analyst & Ambassador Comments
Go to original news
Feb 17,2022

DiaMonTech raises $5 million from Samsung Ventures and US venture capitals

DiaMonTech today announced a $5 million investment round, bringing total funding to over $20 million. The addition of Samsung Ventures and a global medical technology company as strategic partners reinforces DiaMonTech's ambition to revolutionize non-invasive diabetes management.

FUNDING VENTURE ROUND
View Analyst & Ambassador Comments
Go to original news
Feb 22,2022

Medtronic’s diabetes business dips but CEO says growth will come

Medtronic (NYSE:MDT) announced growth in three out of four segments for the third quarter, with diabetes the only one to slide year-over-year. The Fridley, Minnesota-based medtech giant saw third-quarter revenue growth in its cardiovascular segment (3.4%), medical-surgical segment (1.2%) and neuroscience segment (0.8). However, the company’s diabetes business dipped 7.3% year-over-year in sales.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES